Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.
Antonios DourosJulie RouetteHui YinOriana Hoi Yun YuKristian B FilionLaurent AzoulayPublished in: Diabetes care (2019)
In this large population-based study, use of DPP-4 inhibitors was associated with an at least doubling of the risk of BP in patients with type 2 diabetes, albeit the absolute risk was low.
Keyphrases